A. Colevas, C.H. Chung, D. Adkins, C. Rodriguez, J.C. Park, M. Gibson, A. Sukari, B. Burtness, F. Johnson, R.A. Julian, N. Saba, F. Worden, L. Dunn, T. Seiwert, R. Jotte, R. Haddad, N. Gabrail, J. Bauman, S. Margossian, S. Pai
{"title":"CUE-101作为单药用于三线治疗以及与Pembrolizumab联合用于一线复发/转移性(R/M)HPV16+头颈癌患者的1期剂量递增和扩展研究","authors":"A. Colevas, C.H. Chung, D. Adkins, C. Rodriguez, J.C. Park, M. Gibson, A. Sukari, B. Burtness, F. Johnson, R.A. Julian, N. Saba, F. Worden, L. Dunn, T. Seiwert, R. Jotte, R. Haddad, N. Gabrail, J. Bauman, S. Margossian, S. Pai","doi":"10.1016/j.ijrobp.2024.01.192","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14219,"journal":{"name":"International Journal of Radiation Oncology*Biology*Physics","volume":"46 18","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Phase 1 Dose-escalation and Expansion Study of CUE-101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+ Head and Neck Cancer Patients\",\"authors\":\"A. Colevas, C.H. Chung, D. Adkins, C. Rodriguez, J.C. Park, M. Gibson, A. Sukari, B. Burtness, F. Johnson, R.A. Julian, N. Saba, F. Worden, L. Dunn, T. Seiwert, R. Jotte, R. Haddad, N. Gabrail, J. Bauman, S. Margossian, S. Pai\",\"doi\":\"10.1016/j.ijrobp.2024.01.192\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":14219,\"journal\":{\"name\":\"International Journal of Radiation Oncology*Biology*Physics\",\"volume\":\"46 18\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology*Biology*Physics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2024.01.192\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology*Biology*Physics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2024.01.192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Phase 1 Dose-escalation and Expansion Study of CUE-101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+ Head and Neck Cancer Patients